CNMD · CONMED Corporation

The thesis

CONMED Corporation's shares rest on a guided operating recovery and an unconfirmed July sale report; the third-quarter results due after the close on 28 October 2026 settle whether the operating case holds. The adjusted close on 27 October 2026 was $47.20, 9.0% below the 52-week high of $51.86 and above the $45 Piper Sandler and $46 Wells Fargo analyst targets.

The narrative is maturing: Bloomberg's sale report dates to 10 July 2026, and searches through 28 October 2026 find no company confirmation, named bidder or timetable since. The company guided third-quarter sales to $334 million–$339 million and adjusted earnings per share to $0.98–$1.03 on 29 July 2026. Results against that range decide the price unless a transaction is disclosed first.

Bullish and bearish views on CONMED Corporation

The bull case on CONMED Corporation (CNMD), in brief: Second-quarter sales beat estimates. The bear case: The sale report has not progressed.

Bull case

• Second-quarter sales beat estimates. CONMED's 29 July 2026 release reported sales of $343.488 million against a $337.564 million analyst estimate (Benzinga).
• Full-year earnings guidance was raised. On 29 July 2026 the company guided FY2026 adjusted earnings per share to $4.48–$4.60 against a $4.34 analyst estimate. Sales guidance was narrowed to $1.358 billion–$1.373 billion from $1.350 billion–$1.375 billion.
• Third-quarter growth guidance is above the second-half range. The company guided third-quarter organic constant-currency growth to 6.4%–7.6% in its 29 July 2026 release. Chief Financial Officer John Gallagher repeated second-half guidance of 6%–8% at the Wells Fargo healthcare conference on 9 September 2026.
• A product catalyst is in market. On 22 July 2026 CONMED said its AirSeal robotic solution is indicated for use with Intuitive's 8 mm hex cannulas on the da Vinci 5 platform. Gallagher said on 9 September 2026 that he expects further AirSeal acceleration.
• Private-equity interest was reported. Bloomberg reported on 10 July 2026 that CONMED was weighing a sale after takeover interest from private-equity firms, and the shares rose about 10% after hours. JPMorgan said the company would "look highly attractive to financial acquirers."

Bear case

• The sale report has not progressed. No bidder, agreement or timetable appears in the 9 September 2026 conference remarks or in searches through 28 October 2026. A company statement ending sale consideration would remove the premium the July move priced in.
• Second-quarter earnings included a one-off. The 29 July 2026 earnings call attributed $0.21 per share of second-quarter adjusted earnings to a tariff refund outside guidance. Third-quarter adjusted earnings per share guidance of $0.98–$1.03 sits well below the $1.38 second-quarter figure.
• Cash flow guidance was cut. MarketBeat's summary of the 29 July 2026 call reported that the free-cash-flow outlook was lowered to about $115 million.
• The shares trade above two analyst targets. On 30 July 2026 Piper Sandler (Neutral) set a $45 target and Wells Fargo (Equal-Weight) set $46. BMO initiated at Market Perform with a $36 target on 9 July 2026. Argus lowered its target to $49 on 9 September 2026.
• Second-quarter reported sales rose 0.3% against 6.0% organic constant-currency growth.

Price setup

The adjusted daily close was $47.20 on 27 October 2026, up from $44.93 on 14 October 2026 and $45.42 on 18 September 2026. The shares sit 9.0% below the 52-week high of $51.86 and are up 0.5% over three months, a window that now starts after the July sale-report jump. The 14-day relative strength index (RSI), a momentum gauge, reads 61.3, up from 48.8 on 14 October 2026.

Crowding evidence is limited to the calendar. The report is due after the close on 28 October 2026, and the options market implied a move of about 11.4% as of 15 October 2026 (Unusual Whales). Searches found no SEC Form 4 insider sales or share issuance in the period.

The company beat the consensus earnings estimate in each of its last eight quarters, per one earnings calendar, and the shares have drifted higher since the 29 July 2026 report. The rise into the print leaves the shares above both neutral-rated targets before results arrive.

Catalysts, next 30 days

• Undated: Any company statement or filing on the strategic-alternatives review. None has a confirmed timetable.

Elapsed catalysts

• 28 October 2026: Third-quarter 2026 results after the close, with a call at 4:30 p.m. ET. The test is sales of $334 million–$339 million, adjusted earnings per share of $0.98–$1.03 and organic constant-currency growth of 6.4%–7.6%. (passed 9d ago)
• 2 November 2026: Former CFO Todd Garner's adviser role ends, completing the handover to Gallagher, who took over on 15 July 2026. (passed 4d ago)

What would change the view

The operating case breaks if third-quarter sales come in below $334 million, if organic constant-currency growth falls under 6%, or if full-year adjusted earnings per share guidance of $4.48–$4.60 is cut. A company statement ending sale consideration would remove the takeover premium regardless of the quarter.

The price condition is a daily close below $43, which would put the shares well under the 18 September 2026 close of $45.42 and below the October range. A disclosed bid or definitive agreement would shift the debate from operating results to deal terms and would be a new fact for the case.

What it trades with

CONMED trades with mid-cap medical-device companies on orthopedic and surgical procedure volumes, and with small- and mid-cap takeover candidates when deal news appears. Its AirSeal product ties part of the growth story to Intuitive Surgical's da Vinci 5 platform. The July sale report links the shares to private-equity deal activity in medical devices, so a transaction elsewhere in the sector can move them without any CONMED news.